Background and objective: Hesperetin and naringenin, the aglycones of the flavanone glycosides hesperidin and naringin, occur naturally in citrus fruits. They exert interesting pharmacological properties such as antioxidant, anti-inflammatory, blood lipid and cholesterol lowering and are considered to contribute to health benefits in humans. However, no information is available on the pharmacokinetics of the citrus flavanones hesperetin and naringenin after their oral administration to humans as pure aglycones. Therefore, the objective of the present investigation was the evaluation of the pharmacokinetic parameters of hesperetin and naringenin in plasma and urine, after their single oral administration in humans in the form of solid dispersion capsules, and also to improve the absorption rate of flavanones by using aglycones rather than the naturally occurring glycosides. Design: Six healthy volunteers received orally 135 mg of each compound, hesperetin and naringenin, under fasting conditions. Blood samples were collected at 14 different time points over a 12 h period. Urine was collected over 24 h, in five sequential timed intervals. Plasma and urine hesperetin and naringenin concentrations, after enzymatic hydrolysis of their conjugated forms, were measured using validated high-pressure liquid chromatography methods. Pharmacokinetic parameters for hesperetin and naringenin, such as C max , T max , AUC 0Àt , AUC 0ÀN , CL/F, V/F, t 1/2 , MRT, A e , A e ( 0-24 ), and R max were calculated from their plasma or urine concentrations. Results: Pharmacokinetic analysis showed that both hesperetin and naringenin were rapidly absorbed and their concentrations in plasma observed 20 min after dosing and reached a peak in 4.0 and 3.5 h, respectively. The mean peak plasma concentration (C max ) for hesperetin and naringenin were 825.787410.63 ng/ml (2731.871358.4 nmol/l) and 2009.517770.82 ng/ml (7386.672833.4 nmol/l), respectively and the mean AUC 0ÀN values were 4846.2071675.99 ng h/ml and 9424.527 2960.52 ng h/ml for hesperetin and naringenin, respectively. The elimination half-life for hesperetin was found to be 3.0570.91 h and for naringenin 2.3170.40 h, respectively. The mean values of the relative cumulative urinary excretion, as percentage of the administered dose, for hesperetin and naringenin, were found to be 3.2670.44 and 5.8170.81%, respectively. Conclusions: Oral administration of the flavanone aglycones, hesperetin and naringenin, lead to their rapid absorption as their conjugated forms. The cumulative urinary recovery data indicated low bioavailability for both flavanone aglycones, owing to extensive first-pass metabolism partly by cleavage of the C-ring by the enzymes of intestinal bacteria leading to degradation products such as phenolic acids.
Introduction
Flavonoids are polyphenolic plant secondary metabolites ubiquitous in foods of plant origin (Havsteen, 1983) . They occur naturally as glycosides and consist of flavones, flavonols, flavanones and isoflavones (Rice-Evans et al., 1996) . Hesperidin and naringin are the main flavanone glycosides naturally occurring in citrus fruits (Rouseff et al., 1987; Kanaze et al., 2003) . They exert antioxidant (RiceEvans et al., 1996; Miyake et al., 1998; Franke et al., 2005) , anti-inflammatory (Crespo et al., 1999) , blood lipid and cholesterol-lowering (Montforte et al., 1995; Bok et al., 1999; Lee et al., 1999; Santos et al., 1999) and anticarcinogenic activities Yang et al., 1997; Berkarda et al., 1998) . Epidemiological studies indicate an association between the intake of citrus fruits and juices and the risk of ischemic stroke (Joshipura et al., 1999) . They also alter the pharmacokinetics of a variety of clinically used drugs resulting in drug interactions by inhibiting selected cytochrome P-450 enzymes, such as CYP1A2 and CYP3A4 (Ghosal et al., 1996) .
The flavanone glycosides hesperidin and naringin are both rutinosides, that is, the aglycone is linked to glucose and rhamnose sugars at position 7. Flavonoid glycosides, bearing rutinose groups, are hydrolyzed only in the distal part of the intestine and the colon by colonic bacteria, in contrast to flavonoid glucosides, bearing a glucose moiety, which are hydrolyzed already in the small intestine by beta-glucosidases. The released aglycones, hesperetin and naringenin, are recovered in plasma as glucuronides and sulphoglucuronides (Hacket et al., 1979; Fuhr and Kummert, 1995; Jang and Kim, 1996; Choudhury et al., 1999; Felgines et al., 2000; Nielsen et al., 2006) . Different studies indicate that the aglycone release is the rate-limiting step for their absorption (Manach et al., 2003) . The flavanone aglycones mentioned also undergo conversion into phenolic acids by means of the cleavage of the C-ring by enzymes of the intestinal microflora (Kim et al., 1998) . The conjugated flavanone aglycones are excreted in urine (Lee and Reidenberg, 1998; Erlund et al., 2001) . Moreover, an enterohepatic cycling seems to take place (Manach et al., 2003) .
To the best of our knowledge, no information is available on the bioavailability and pharmacokinetics of flavanones in humans when provided as pure aglycones. Therefore, the objective of the present investigation was to evaluate the pharmacokinetic parameters of hesperetin and naringenin in plasma and urine, after their single oral dose to healthy subjects in the form of solid dispersion system formulations (Kanaze et al., 2006a, b) and also to improve the absorption rate of flavanones by using aglycones rather than the naturally occurring glycosides.
Materials and methods

Chemicals
Hesperetin (( þ )-3 0 ,5,7-trihydroxy-4 0 -methoxyflavanone), 95%, naringenin ((7)-4 0 ,5,7-trihydroxyflavanone), 95%, internal standard 7-ethoxycoumarin and b-glucuronidase/sulphatase (aqueous solution from Helix pomatia, Type HP-2, G7017) were purchased from Sigma (St Louis, MO, USA). Highpressure liquid chromatography (HPLC)-grade methanol, acetonitrile and acetic acid were obtained from Merck (Darmstadt, Germany). Bakerbond C18 cartridges, 3-ml 500 mg, were supplied from JT Baker (Deventer, The Netherlands). All other chemicals and solvents used were of analytical grade.
Subjects
The study population included six healthy adult volunteers (five males, one female). All subjects were in good health as assessed by medical history, clinical examination, blood pressure and routine laboratory examinations. The subjects were instructed to abstain from taking any medication including over-the-counter drugs for at least 7 days prior or during the course of the study period and avoiding alcohol or xanthine-containing foods and beverages 36 h before, or during the course of the study, in order to avoid possible drug-drug interactions leading to increased variability of the pharmacokinetic parameters. The subjects have also been requested not to consume foods that contain citrus flavanones (e.g. citrus fruits in any form, tomatoes and tomato sauce and paste, etc.) and they were given a list of prohibited foods.
All subjects were given a detailed description of the study and their informed consent was obtained. The study was performed in accordance with the guidelines of the revised Declaration of Helsinki on biomedical research involving subjects and the requirements of Good Clinical Practice.
Study design and sampling
After an overnight fast of at least 10 h, each subject received a single oral dose (capsule) of 135 mg of each flavanone aglycone, hesperetin and naringenin, along with 240 ml of water. No food was allowed until a standardized flavanonefree meal, consisting of white bread, chicken, rice, salad with vinaigrette dressing, and water, was served 4 h after dosing. Blood pressure and pulse were checked before, during and after the end of the study.
A vein-probe was implemented to each volunteer and blood samples (5 ml) were drawn from each subject into heparinized test tubes immediately before (0) and at 20, 35, 50, 70, 100, 150 min and at 3, 4, 5, 6, 8, 10 and 12 h. Blood samples were centrifuged at 41C at 3500 g for 20 min, and plasma was separated and kept frozen at À201C in coded polypropylene tubes pending analysis.
Urine was collected in five sequential intervals: 0-3, 3-6, 6-9, 9-12 and 12-24 h after drug administration. The volume of each fraction was measured and an aliquot of 10 ml was transferred into polypropylene tubes and stored frozen at À201C until analysis.
Quantitative analysis of hesperetin and naringenin in plasma and urine samples Quantitative analysis of hesperetin and naringenin in plasma and urine samples was conducted using previously reported validated HPLC methods (Kanaze et al., 2004a, b) . In brief, plasma and urine samples containing 7-ethoxycoumarin as internal standard were incubated with bglucuronidase (4000 U) and sulphatase (300 U) (aqueous solution from Helix pomatia, Type H-2, Sigma G7017) for 18 h at 371C, in order to hydrolyze the conjugated forms of hesperetin and naringenin, followed by solid phase extraction using C18 cartridges. The chromatographic separation of hesperetin, naringenin and internal standard was achieved on a 5-mm C8 analytical column (250 Â 4.6 mm i.d.) using a mobile phase consisting of methanol/distilled water/acetic acid (40/58/2, v/v/v). The HPLC system was operated isocratically at a flow rate of 1 ml/min at 451C and absorbance of the eluent was monitored at 280 nm. Quantification of the unconjugated flavanone aglycones, hesperetin and naringenin, was determined by linear regression analysis of peak height ratios versus concentrations of added hesperetin and naringenin. The calibration curves were linear with a correlation coefficient better than 0.999 and the lower limit of quantification for both hesperetin and naringenin was 10 and 50 ng/ml for 1-ml plasma and urine samples, respectively.
Pharmacokinetic evaluation
The pharmacokinetic parameters of hesperetin and naringenin were estimated using standardized model-independent methods (Gibaldi and Perrier, 1982; Rowland and Tozer, 1995) . Calculations were carried out with the Siphar/Win package (Simed, Creteil, France).
The maximum plasma concentration (C max ) value and the corresponding time that the latter is marked (T max ), were taken directly from the individual plasma data. The elimination rate constant (k) was obtained by means of linear regression analysis of the semi-logarithmic plasma concentration-time curve and the elimination half-life (t 1/2 ) was calculated by dividing ln 2 by k. The area under the plasma concentration-time curve from administration to the last observed concentration at time t (AUC 0Àt ) and the area under the first moment of the plasma concentration-time curve from administration to the last observed concentration at time t (AUMC 0Àt ) were estimated by the use of the linear trapezoidal method, according to the following equations:
where t i is the ith time point, C i is the ith available concentration and n is the number of data points. The area under the plasma concentration-time curve extrapolated to infinitive time (AUC 0ÀN ) and the area under the first moment of the plasma concentration-time curve extrapolated to infinitive time (AUMC 0ÀN ) were estimated by the following equations:
where C n is the last measurable concentration and t n is the time point of the last measurable concentration. The amount of hesperetin and naringenin excreted into urine during each collection interval (A e ) was determined by multiplying the urine concentration of the drug by the volume of urine collected for each interval. The cumulative amount of hesperetin and naringenin excreted into urine over the entire period of sample collection (0-24 h) ðA e0-24 Þ was calculated by adding the amount excreted over each collection interval. The rate of drug excretion during each collection interval (R) was determined by dividing the amount excreted in each collection interval by the sampling interval. The maximum rate of drug excretion (R max ) and the time of the maximum excretion rate (t max ) were derived as the midpoint of the collection interval during which R max occurred.
Results
All six subjects successfully completed the pharmacokinetic study and none reported undesirable or adverse effects after oral administration of the flavanone aglycones, hesperetin and naringenin. All subjects who participated in the study were discharged in good health. Descriptive statistics of the demographic data are summarized in Table 1 .
Previous studies indicated that hesperetin and naringenin are found in human plasma and urine almost exclusively as their conjugated forms, glucuronides and sulphoglucuronides (Manach et al., 2003) . In our study, hesperetin and Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin FI Kanaze et al naringenin were quantitated in plasma and urine after hydrolysis of samples with b-glucuronidase/sulphatase and therefore the results represent total hesperetin and naringenin concentrations. None of the subjects had measurable concentrations of either hesperetin or naringenin in plasma or urine at baseline. The mean7s.d. plasma hesperetin and naringenin concentration-time curves are illustrated in Figure 1 . The inter-individual variability of the plasma hesperetin and naringenin concentrations was fairly low throughout the study. Both flavanone aglycones were absorbed from the gastrointestinal tract and they were measurable in almost all subjects 20 min following oral administration. Descriptive statistics of the pharmacokinetic parameters in plasma for hesperetin and naringenin are summarized in Table 2 . Figure 2 illustrates the mean7s.e.m. cumulative urinary excretion data for hesperetin and naringenin. For both flavanone aglycones, urinary excretion started in the 0-3 fraction, the maximum excretion rate (R max ) occurred in 4.5 h (in the 3-6 h fraction), and was complete in 24 h. The urinary recoveries for hesperetin and naringenin were 3.2670.44 and 5.8170.81% of the administered dose, respectively (Table 3) . Abbreviations: AUC 0-N , area under the plasma concentration-time curve extrapolated to infinitive time; AUC 0-t , area under the plasma concentration-time curve from administration to the last observed concentration at time t; C max , maximum plasma concentration; CL/F, total clearance; MRT, mean residence time; t 1/2 , elimination half-life; V/F, volume of distribution. 
Discussion
The main objective of the present study was to evaluate the plasma and urine pharmacokinetic parameters of hesperetin and naringenin, after their single oral administration in humans in the form of solid dispersion capsules. Secondary objective of the study was also to improve their absorption rate and to decrease the inter-individual variability of the pharmacokinetic parameters concerning the rate and extent of absorption. Different animal and human studies indicate that the flavanone glycosides hesperidin and naringin, are most likely hydrolyzed by colonic bacteria into their flavanone aglycones, hesperetin and naringenin which are subsequently absorbed into the systematic circulation as glucuronides and sulphoglucuronides (Hacket et al., 1979; Bokkenheuser et al., 1987; Fuhr and Kummert, 1995; Jang and Kim, 1996; Choudhury et al., 1999; Hollman et al., 1999; Felgines et al., 2000; Erlund et al., 2001; Nielsen et al., 2006) . However, trace amounts of the flavanone glycosides, for example, naringin, can be absorbed intact (Ishii et al., 2000) . The flavanone glycosides hesperidin and naringin are both rutinosides, and therefore are not hydrolyzed by the betaglucosidases in the small intestine, but they are hydrolyzed in the distal part of the intestine and the colon by the enteric microflora. Hydrolysis of the flavanone glycosides to their aglycones is probably the rate-limiting step for their absorption (Erlund et al., 2001; Manach et al., 2003; Nielsen et al., 2006) . In contrast, the absorption site of the flavonoid aglycones and the flavonoid glucosides, which are hydrolyzed by beta-glucosidases, is the small intestine where they are absorbed much faster (Nielsen et al., 2006) . Differences in the enteric microflora may be responsible for considerable inter-individual variability regarding the absorption pharmacokinetic parameters (Erlund et al., 2001) .
The absorption of both hesperetin and naringenin was rapid and much faster than that in previous studies after oral administration of their flavanone glycosides, hesperidin and naringin, either as pure compounds or in the form of citrus juices (Ameer et al., 1996; Erlund et al., 2001; Manach et al., 2003) , reflecting the omission of the hydrolytic step. Also, the inter-individual variability of the pharmacokinetic parameters related to absorption, for example, AUC, C max and T max , was fairly low in comparison with that observed in other studies where the flavanone glycosides were administered in the form of citrus juices or as pure compounds (Ameer et al., 1996; Erlund et al., 2001) . Additionally, it is prominent that when citrus flavanones are administered as their aglycones, hesperetin and naringenin, their urinary excretion starts within the first time interval (0-3 h) and reaches their maximum excretion rate in the second fraction (3-6 h), whereas in the case of their administration as flavanone glycosides, their urinary excretion starts fairly later (Erlund et al., 2001; Manach et al., 2003) . It is well known that flavonoid glycosides demonstrate significant transient time before reaching the distal part of the small intestine or the colon where they undergo sugar cleavage and absorption of their aglycones (Ameer et al., 1996; Manach et al., 2003 , Nielsen et al., 2006 . The values of the elimination half-life (t 1/2 ) for hesperetin and naringenin were found to be comparable to those estimated previously, in experiments where the flavanone glycosides were administered in the form of citrus juices (Erlund et al. 2001) .
The relative cumulative urinary excretion, expressed as percentage of the administered dose, which may be considered as an estimator of the oral bioavailability, was found to be 3.26 and 5.81% for hesperetin and naringenin, respectively, almost comparable than the corresponding values in other studies, where the flavanone glycosides, hesperidin and naringin, were administered as pure compounds (Ameer et al., 1996; Ishii et al., 2000) . However, the cumulative urinary recovery data indicated low bioavailability for both flavanone aglycones, possibly owing to extensive first-pass metabolism partly by cleavage of the C-ring by the enzymes of intestinal bacteria leading to degradation products such as phenolic acids (Booth et al., 1958; Felgines et al., 2000) .
To our knowledge, this is the first report to evaluate the pharmacokinetic parameters in plasma and urine of the flavanone aglycones, hesperetin and naringenin, after their single oral administration in humans in the form of solid dispersion formulations. 
